| Random subspace ensembles for fMRI classification LI Kuncheva, JJ Rodríguez, CO Plumpton, DEJ Linden, SJ Johnston IEEE transactions on medical imaging 29 (2), 531-542, 2010 | 288 | 2010 |
| A systematic review of economic evaluations of pharmacogenetic testing for prevention of adverse drug reactions CO Plumpton, D Roberts, M Pirmohamed, DA Hughes Pharmacoeconomics 34, 771-793, 2016 | 163 | 2016 |
| The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non … A Marson, G Burnside, R Appleton, D Smith, JP Leach, G Sills, ... The Lancet 397 (10282), 1375-1386, 2021 | 157 | 2021 |
| The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority … A Marson, G Burnside, R Appleton, D Smith, JP Leach, G Sills, ... The Lancet 397 (10282), 1363-1374, 2021 | 155 | 2021 |
| Predictors of self-reported adherence to antihypertensive medicines: a multinational, cross-sectional survey VL Morrison, EAF Holmes, S Parveen, CO Plumpton, W Clyne, ... Value in Health 18 (2), 206-216, 2015 | 132 | 2015 |
| PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron … P Ghaneh, R Hanson, A Titman, G Lancaster, C Plumpton, ... Health Technology Assessment 22 (7), 2018 | 113 | 2018 |
| Multiple imputation of multiple multi-item scales when a full imputation model is infeasible CO Plumpton, T Morris, DA Hughes, IR White BMC research notes 9, 1-15, 2016 | 78 | 2016 |
| Cost‐effectiveness of screening for HLA‐A*31:01 prior to initiation of carbamazepine in epilepsy CO Plumpton, VLM Yip, A Alfirevic, AG Marson, M Pirmohamed, ... Epilepsia 56 (4), 556-563, 2015 | 69 | 2015 |
| Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout CO Plumpton, A Alfirevic, M Pirmohamed, DA Hughes Rheumatology 56 (10), 1729-1739, 2017 | 57 | 2017 |
| Conducting economic evaluations alongside randomised trials: current methodological issues and novel approaches D Hughes, J Charles, D Dawoud, RT Edwards, E Holmes, C Jones, ... Pharmacoeconomics 34, 447-461, 2016 | 56 | 2016 |
| The cancer care experiences of gay, lesbian and bisexual patients: A secondary analysis of data from the UK Cancer Patient Experience Survey NJ Hulbert‐Williams, CO Plumpton, P Flowers, R McHugh, RD Neal, ... European journal of cancer care 26 (4), e12670, 2017 | 55 | 2017 |
| Linear mixed models to handle missing at random data in trial‐based economic evaluations A Gabrio, C Plumpton, S Banerjee, B Leurent Health Economics 31 (6), 1276-1287, 2022 | 50 | 2022 |
| Adaptive learning rate for online linear discriminant classifiers LI Kuncheva, CO Plumpton Structural, Syntactic, and Statistical Pattern Recognition: Joint IAPR …, 2008 | 48 | 2008 |
| Societal preferences for funding orphan drugs in the United Kingdom: an application of person trade-off and discrete choice experiment methods SM Bourke, CO Plumpton, DA Hughes Value in Health 21 (5), 538-546, 2018 | 47 | 2018 |
| Naive random subspace ensemble with linear classifiers for real-time classification of fMRI data CO Plumpton, LI Kuncheva, NN Oosterhof, SJ Johnston Pattern Recognition 45 (6), 2101-2108, 2012 | 47 | 2012 |
| Attitudes towards epilepsy in the UK population: results from a 2018 national survey E Holmes, S Bourke, C Plumpton Seizure 65, 12-19, 2019 | 44 | 2019 |
| Choosing parameters for random subspace ensembles for fMRI classification LI Kuncheva, CO Plumpton International workshop on multiple classifier systems, 54-63, 2010 | 36 | 2010 |
| Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT. AV Ramanan, AD Dick, AP Jones, DA Hughes, A McKay, A Rosala-Hallas, ... Health Technology Assessment (Winchester, England) 23 (15), 1, 2019 | 33 | 2019 |
| Cost‐effectiveness of panel tests for multiple pharmacogenes associated with adverse drug reactions: An evaluation framework CO Plumpton, M Pirmohamed, DA Hughes Clinical Pharmacology & Therapeutics 105 (6), 1429-1438, 2019 | 32 | 2019 |
| Patient‐Focused Drug Development Methods for Benefit–Risk Assessments: A Case Study Using a Discrete Choice Experiment for Antiepileptic Drugs EAF Holmes, C Plumpton, GA Baker, A Jacoby, A Ring, P Williamson, ... Clinical Pharmacology & Therapeutics 105 (3), 672-683, 2019 | 30 | 2019 |
